332 filings
Page 3 of 17
DEFA14A
1ic o44tlb075qql
18 Aug 23
Additional proxy soliciting materials
4:01pm
8-K
39wis225
11 Aug 23
T2 Biosystems Announces Second Quarter 2023 Financial Results
4:00pm
8-K
9yh730 pntnzuv6n41
9 Aug 23
Regulation FD Disclosure
4:10pm
8-K
v34xx5k ldu6byymr1y
31 Jul 23
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
9:11am
8-K
4ro6ynqocv
20 Jul 23
T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
8:30am
424B5
edpgas7lb 6trm0oi
12 Jul 23
Prospectus supplement for primary offering
8:11am
8-K
l9qt4qbvh
12 Jul 23
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
8:05am
8-K
h741 vwevnvu9
6 Jul 23
Entry into a Material Definitive Agreement
8:08am
8-K
oq0xrv5leo
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:01pm
424B5
jcl1pxq9ts3
9 Jun 23
Prospectus supplement for primary offering
9:00am
8-K
v8kkv2m hxzn9yjzn
9 Jun 23
Regulation FD Disclosure
8:45am
8-K
75k7w1qxfo
5 Jun 23
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
9:00am
424B5
vopirfuhz78r y4
5 Jun 23
Prospectus supplement for primary offering
8:46am
424B5
n8qqi4mo4gytlckve2m
30 May 23
Prospectus supplement for primary offering
5:16pm
8-K
e85ucijaump0mz
30 May 23
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
9:01am
8-K
db608hlwmf g6osu
25 May 23
T2 Biosystems Announces First Quarter 2023 Financial Results
4:55pm